“…In contrast, docetaxel, and to a lesser extent pemetrexed, have more serious side effects including anemia and febrile neutropenia. These differences in side effects have quality of life implications as reflected by health state preference studies [13,14]. In addition, these side effects have cost implications with additional physician visits, hospitalizations, and therapies for side effects, including epogen and neupogen.…”